Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-546

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-546). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pemetrexed For Injection 1000mg Label (Image 01)

Pemetrexed For Injection 1000mg Label (Image 01)
This is a description of Pemetrexed for Injection, a cytotoxic agent that should only be used via an intravenous route. Each single-dose vial contains 1000mg of pemetrexed disodium and 1000mg of manitol, as well as adjustments made with hydrochloric acid or sodium hydroxide to adjust pH. Storage should be kept between 20C to 25C, and the literature should be consulted before the drug is given. This drug is manufactured by Glnd Parma I in India and is intended for use in OncoPoint.*
FDA Label Image

Pemetrexed For Injection 1000mg Carton (Image 02)

Pemetrexed For Injection 1000mg Carton (Image 02)
This is a product description for Pemetrexed for Injection, USP, a cytotoxic agent used for intravenous use only. The medication comes in a single-use vial containing 1000mg/vial. To prepare for use, it needs to be reconstituted with 40mL of 0.9% Sodium Chloride USP injection. The solution needs to be further diluted before use per accompanying instructions. Once reconstituted, the solution should be used within 24 hours and any unused portion should be discarded. Dosage and administration information should be obtained from prescribing information. The medication should be stored between 20°C-25°C and should be protected from excursions of 15°C to 30°C. The product is manufactured in India.*
FDA Label Image

Structure (Image 03)

Structure (Image 03)
FDA Label Image

Figure 1 (Image 04)

Figure 1 (Image 04)
FDA Label Image

Figure 2 (Image 05)

Figure 2 (Image 05)
It seems to be a survival probability chart, with survival time in months as the x-axis and survival probability as the y-axis. The text seems to be showing the survival probability for different time periods, with decreasing probabilities as the time increases.*
FDA Label Image

Figure 3 (Image 06)

Figure 3 (Image 06)
The text appears to be a table of data with headings "Gometabin + Clpi (60)", "J — Pametece Clspain )", and "Patients at Risk". The other columns contain numerical data, possibly related to survival time or medical treatment. However, without more context or information it is difficult to interpret or explain the significance of this data.*
FDA Label Image

Figure 4 (Image 07)

Figure 4 (Image 07)
FDA Label Image

Figure 5 (Image 08)

Figure 5 (Image 08)
This appears to be a graph or chart displaying data related to survival probability. The "Survival Time" is measured in months and is shown on the bottom axis. The "Survival Probability" is shown on the vertical axis. The graph includes a curved line that likely represents the probability of survival over time. There are also some numerical values listed on the graph, but their meaning is unclear without additional context.*
FDA Label Image

Figure 6 (Image 09)

Figure 6 (Image 09)
The text is describing a survival probability chart comparing the outcomes of two groups, Pometocea and Placebo. The chart displays the number of patients at risk for each group, the survival time in months, and the corresponding survival probability. However, due to the errors and inconsistencies, the information presented is not clear and may not be reliable.*
FDA Label Image

Figure 7 (Image 10)

Figure 7 (Image 10)
FDA Label Image

Figure 8 (Image 11)

Figure 8 (Image 11)
This is a table showing the survival probability of patients under treatment with Pematrexed and placebo. The number of patients at risk is shown in each row. It is not possible to interpret the purpose of the "aw", "2" and "108" values as they are incomplete.*
FDA Label Image

Figure 9 (Image 12)

Figure 9 (Image 12)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.